Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME005 in advanced melanoma after failure of prior anti-PD1 + anti-CTLA4 immunotherapy
ACTRN12621001155886Phase 2Active, not recruiting
- Sponsor
- University of Newcastle
- Start
- Sep 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine, carboplatin, ipilimumab and nivolumab in melanoma (2 arms), sponsored by University of Newcastle. Primary endpoints: Clinical benefit rate, Dose-limiting toxicity and 1 more. Started Sep 2021; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12621001155886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001155886.